美国食品和药物管理局批准IMCIVREE用于2岁以下的罕见遗传肥胖症儿童. FDA approves IMCIVREE for children as young as 2 with rare genetic obesity conditions.

林业发展局已核准对年龄只有2岁的儿童使用IMCIVREE(semelonotide),他们患有罕见的遗传形式的肥胖症,包括巴代特-比德尔综合症和特定基因缺陷。 The FDA has approved the use of IMCIVREE (setmelanotide) for children as young as 2 years old with rare genetic forms of obesity, including Bardet-Biedl syndrome and deficiencies in specific genes. 该药物是第一个针对MC4R路径的药物,该路径在这些条件下受损,导致难以忍受的饥饿和肥胖症。 This drug is the first to target the MC4R pathway, which is impaired in these conditions, leading to insatiable hunger and obesity. 临床试验显示体重和饥饿显著减少。 Clinical trials showed significant reductions in weight and hunger.